Evidence map›Paper›PMID 33808994›Full record

ArticleCancers2021

3D Pharmacophore-Based Discovery of Novel K

Žan Toplak, Louise Antonia Hendrickx, Špela Gubič, Štefan Možina, Bojana Žegura, Alja Štern, Matjaž Novak, Xiaoyi Shi, Steve Peigneur, Jan Tytgat and 3 more

Abstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Structure-Function Studies of Sponge-Derived Compounds on the Cardiac CaInternational journal of molecular sciences · 2023
    Article
  6. New Diarylamine KPharmaceutics · 2022
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Žan ToplakFaculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia.
Louise Antonia HendrickxToxicology and Pharmacology, Campus Gasthuisberg, University of Leuven, Onderwijs en Navorsing 2, Herestraat 49, P.O. Box 922, 3000 Leuven, Belgium.
Špela GubičFaculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia.
Štefan MožinaFaculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia.ORCID 0000-0002-7416-6981
Bojana ŽeguraDepartment of Genetic Toxicology and Cancer Biology, National Institute of Biology, Večna pot 111, 1000 Ljubljana, Slovenia.ORCID 0000-0002-5731-0785
Alja ŠternDepartment of Genetic Toxicology and Cancer Biology, National Institute of Biology, Večna pot 111, 1000 Ljubljana, Slovenia.ORCID 0000-0001-7531-1215
Matjaž NovakDepartment of Genetic Toxicology and Cancer Biology, National Institute of Biology, Večna pot 111, 1000 Ljubljana, Slovenia.
Xiaoyi ShiAG Oncophysiology, Max-Planck Institute for Experimental Medicine, Hermann-Rein-Str. 3, 37075 Göttingen, Germany.
Steve PeigneurToxicology and Pharmacology, Campus Gasthuisberg, University of Leuven, Onderwijs en Navorsing 2, Herestraat 49, P.O. Box 922, 3000 Leuven, Belgium.ORCID 0000-0003-0504-5702
Jan TytgatToxicology and Pharmacology, Campus Gasthuisberg, University of Leuven, Onderwijs en Navorsing 2, Herestraat 49, P.O. Box 922, 3000 Leuven, Belgium.
Tihomir TomašičFaculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia.ORCID 0000-0001-5534-209X
Luis A PardoAG Oncophysiology, Max-Planck Institute for Experimental Medicine, Hermann-Rein-Str. 3, 37075 Göttingen, Germany.ORCID 0000-0003-1375-4349
Lucija Peterlin MašičFaculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia.ORCID 0000-0003-0624-8472

Funding

CELSA CELSA/17/047 (KU Leuven)FWO-Vlaanderen G0E7120N, GOC2319N and GOA4919NHorizon 2020 No. 813834-PHIONIC-H2020-MSCA-ITN-2018.Javna Agencija za Raziskovalno Dejavnost RS J1-9192, N1-0098, P1-0245 and CELSA project.KU Leuven PDM/19/164Max-Planck Society Max-Planck Society
6 · The paper itself

Abstract

(1) Background: The voltage-gated potassium channel K

Indexed as

antiproliferative activityhERGion channelsKV10.1pharmacophore modellingvirtual screening

Identifiers

PMID33808994
PMCPMC8002023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.